Download Files:
Talabostat
SKU
HY-13233-Get quote
Category Reference compound
Tags Cancer; Inflammation/Immunology, Dipeptidyl Peptidase, Metabolic Enzyme/Protease
Products Details
Product Description
– Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities[1][2][3].
Web ID
– HY-13233
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C9H19BN2O3
Citations
– Ann Surg Oncol. 2020 Oct;27(11):4337-4347.|bioRxiv. 2023 Jan 17.|bioRxiv. January 25, 2022.|Cells. 2023 Apr 6, 12(7), 1100.|CNS Neurosci Ther. 2022 Nov 15.|Curr Protoc Immunol. 2020 Dec;131(1):e107.|Int Immunopharmacol. 2023 May 12;120:110291.|Int J Biol Sci. 2023; 19(2):465-483.|Iran J Allergy Asthma Immunol. 2021 Mar 17.|J Biol Chem. 2018 Dec 7;293(49):18864-18878. |J Immunol. 2020 Sep 15;205(6):1653-1663.|Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19055-19063. |Sci Signal. 2023 Jan 17;16(768):eabh1083.|Science. 2020 Dec 4;370(6521):eaay2002.|Adv Sci (Weinh). 2023 Jun 21;e2300881.|Anal Chem. 2016 Aug 16;88(16):8309-14. |bioRxiv. 2023 Mar 19.|bioRxiv. 2023 Nov 4.|Cancer Res. 2016 Jul 15;76(14):4124-35. |Cell Rep. 2021 Oct 26;37(4):109904.|Cell. 2023 May 11;186(10):2144-2159.e22.|J Allergy Clin Immunol. 2021 Jun;147(6):2134-2145.e20.|J Biol Chem. 2018 Dec 7;293(49):18864-18878. |J Diabetes Investig. 2021 Sep 8.|J Exp Med. 2022 Oct 3;219(10):e20212117.|Nat Commun. 2019 May 7;10(1):2091.|Obesity. 2020 Dec 20.|Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120.|SSRN. 2020 Jul.
References
– [1]Lankas GR, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005 Oct;54(10):2988-94.|[2]Connolly BA, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potencyand in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13.|[3]Talabostat|[4]Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80.
CAS Number
– 149682-77-9
Molecular Weight
– 214.07
SMILES
– CC(C)[C@H](N)C(N1[C@H](B(O)O)CCC1)=O
Clinical Information
– Phase 3
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : ≥ 40 mg/mL
Target
– Dipeptidyl Peptidase
Isoform
– DPP-4
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.